Reagents & Kits Segment to Grow at Faster Pace During Forecast Period
According to The Insight Partners market research study of “North America Liquid Biopsy Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Product & Service, Sample, Circulating Biomarker, Application and End User,” the North America liquid biopsy market is projected to reach US$ 3,531.44 million by 2027 from US$ 1,651.23 million in 2019. The market is estimated to grow at CAGR of 10.1% from 2020 to 2027. The report highlights trends prevailing in the North America liquid biopsy market and the factors driving market along with those that act as hindrances.
The North America liquid biopsy market, based on product & service, is further segmented into equipment, reagents & kits and services. The reagents & kits segment held a larger share of the market in 2019, and the similar segment is estimated to register a higher CAGR during the forecast period owing to the availability of complete set of kits for liquid biopsy is likely to drive the growth for liquid biopsy market during the forecast period.
The North America liquid biopsy market is expected to grow owing to increasing prevalence of cancer in the region. However, low sensitivity of liquid biopsy is likely to restrain the growth of the market during the forecast period.
Moreover, in the United States, due to an increasing number of infected patients, healthcare professionals and leading organizations are distracting the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. Furthermore, the pandemic spread is also preventing the clinical trials, drug development, and diagnostic industry in the US. For instance, California-based Lucence Diagnostics Pte Ltd., who develops liquid biopsy and has a known player in this industry, has been diverted now to manufacture kits for COVID-19.
Leading companies operating in the Liquid Biopsy market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Biocept, Inc, Inivata Ltd, among others.
North America Liquid Biopsy Market, By Country, 2019 (%)
North America Liquid Biopsy Market to Grow at a CAGR of 10.1% to reach US$ 3,531.44 Million from 2020 to 2027
Download Free Sample
North America Liquid Biopsy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product & Services (Equipment, Reagents & Kits and Services); Sample (Blood Based, Urine Based and Other samples); Circulating Biomarker (Circulating Tumor Cells (CTC), Exosomes and Free Nucleic Acid); Application (Noninvasive Prenatal Testing (NIPT), Oncology, Transplant Diagnostics and Other Applications); End User (Academic & Research Institutes, Hospitals, Reference Laboratories and Other End Users); and, Country
North America Liquid Biopsy Market to Grow at a CAGR of 10.1% to reach US$ 3,531.44 Million from 2020 to 2027
Download Free SampleNorth America Liquid Biopsy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product & Services (Equipment, Reagents & Kits and Services); Sample (Blood Based, Urine Based and Other samples); Circulating Biomarker (Circulating Tumor Cells (CTC), Exosomes and Free Nucleic Acid); Application (Noninvasive Prenatal Testing (NIPT), Oncology, Transplant Diagnostics and Other Applications); End User (Academic & Research Institutes, Hospitals, Reference Laboratories and Other End Users); and, Country
The report segments North America Liquid Biopsy Market as follows:
By Product & Service
- Equipment
- Reagents & Kits
- Services
By Sample
- Blood Based
- Urine Based
- Other samples
By Circulating Biomarker
- Circulating Tumor Cells (CTC)
- Exosomes
- Free Nucleic Acid
By Application
- Noninvasive Prenatal Testing (NIPT)
- Oncology
- Transplant Diagnostics
- Other Applications
By End User
- Academic & Research Institutes
- Hospitals
- Reference Laboratories
- Other End Users
By Country
- US
- Canada
- Mexico